【药闻医讯 一周速览 】 中检院关于发布《药品注册检验工作程序和技术要求规范 (2025年修订版)》的通告；千亿巨头再出手！中国生物制药收购礼新医药；减重19.2%！恒瑞这款双靶点减重药Ⅲ期数据揭晓…… ...

2025年7月14日，美国马萨诸塞州，全球分析仪器领导者Waters Corporation（纽约证券交易所代码：WAT）宣布，已与医疗技术巨头Becton, Dickinson & Company（BD，纽约证券交易所代码：BDX）达成最终协议，将整合BD旗下生物科学及诊断解决方案业务。此次交易通过反向莫里斯信托（Reverse Morris ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

Author Andrea Randall wrote that "Heroes don't always wear capes, badges or uniforms. Sometimes they support those who do." Nothing could be more true of the hundreds of people who ...

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

A deal for Becton Dickinson’s biosciences and diagnostic solutions unit puts Waters Corp. in a greater position to compete ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Waters Corporation is merging with BD’s Biosciences and Diagnostic Solutions business in a $17.5 billion deal to expand its capabilities in life sciences and diagnostics.

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Waters Corporation (WAT) stock downgraded at Wells Fargo based on execution risks related to its $17.5B M&A deal with a unit of Becton Dickinson (BDX). Read more here;.

Investing.com - TD Cowen重申对贝克顿迪金森 (Becton Dickinson, NYSE:BDX)的持有评级，目标价为183.00美元，此前该公司宣布了战略重组计划。根据 InvestingPro 分析，该公司目前交易价格为177.48美元，似乎被低估，分析师目标价范围从172美元到320.55美元不等。